Could GlaxoSmithKline Be A Better Investment Than Gilead?
- GlaxoSmithKline has declined this year while Gilead has risen.
- Glaxo has a new HIV therapy that could take market share from Gilead.
- Glaxo's pipeline should lead it back to growth in 2015.
- But Gilead is likely to continue to outperform Glaxo in the short run.